REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests a combination of two drugs, acalabrutinib and venetoclax, in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to treatment. The goal is to see if this combo can reduce cancer cells to undetect…

This early-stage trial tests a new drug called Q702 in people with certain blood cancers or related diseases that have not responded to other treatments. The drug works by helping the immune system attack cancer cells and supporting normal blood cell production. The study will ch…

This study tests a drug called mirdametinib in 20 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The drug blocks a protein that helps cancer cells grow. The goal is to see if it can shrink tumor…

This study tests whether a faster dose increase of the drug sonrotoclax, given with other medicines, is safe for people with certain blood cancers (CLL, SLL, or mantle cell lymphoma). The cancers may be new, returned, or not responding to treatment. The goal is to see if this qui…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This early-phase trial tests a new type of CAR T-cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target three cancer marker…

This study tests whether a combination of two targeted drugs (acalabrutinib and venetoclax) with or without an early dose of a third drug (obinutuzumab) can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that is high-risk, has returned, or s…

This early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…

This study collects blood, bone marrow, or lymph node samples from 60 people with chronic lymphocytic leukemia (CLL) who are taking or about to take BTK degraders. Researchers will analyze the samples to find out why some patients stop responding to these drugs. The goal is to be…